Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Lymphoma
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Lymphoma
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Lymphoma
Description
A general term for various neoplastic diseases of the lymphoid tissue. MeSH
Hierarchy View
Subtype Terms (5)
Composite Lymphoma
8 drugs (7 approved, 1 experimental)
Hodgkin Disease
403 drugs (178 approved, 225 experimental)
Immunoproliferative Small Intestinal Disease
Intraocular Lymphoma
75 drugs (47 approved, 28 experimental)
Lymphoma, Non-Hodgkin
730 drugs (240 approved, 490 experimental)
Phase 3 Indicated Drugs (143)
Phase 2 Indicated Drugs (308)
adenovirus type-5 vectored covid-19 vaccine
allogeneic bone marrow derived mesenchymal stem cell
allogeneic car19 regulatory t cells (car19-ttreg)
allogeneic epstein-barr virus specific cytotoxic t-lymphocytes
allogeneic natural killer cells
anti-cd19/20-car vector-transduced t cells
autologous-allogeneic tandem hematopoietic stem cell
autologous cd19/cd22 chimeric antigen receptor t-cells
autologous epstein-barr virus-specific cytotoxic t lymphocytes
autologous hematopoietic stem cells
autologous mononuclear stem cell
autologous umbilical cord blood
axicabtagene ciloleucel (Yescarta)
Bismuth Subcitrate Potassium (Pylera)
brentuximab vedotin (adcetris)
cord blood hematopoietic stem cell
cytomegalovirus-specific cytotoxic t cells
dec-205/ny-eso-1 fusion protein cdx-1401
in vitro-treated peripheral blood stem cell
lymphocyte immune globulin, anti-thymocyte globulin (equine) (Atgam)
multi-peptide cmv-modified vaccinia ankara vaccine
Phase 1 Indicated Drugs (339)
allogeneic gamma-delta t cells
anti-cd19-car gamma-delta t cells
autologous ade1- latent membrane protein ctls
autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes
autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
autologous differentiated t-cells
autologous ebv specific cytotoxic t lymphocytes
autologous humanized anti-cd19 and anti-cd20 dual specific car-t cells
autologous lymphoma immunoglobulin-derived scfv-chemokine dna vaccine
barf1-specific cytotoxic t-lymphocytes
cd56-enriched donor lymphocyte
donor memory t cells that have been depleted of cd62l+
ebna1 c-terminal/lmp2 chimeric protein-expressing recombinant modified vaccinia ankara vaccine
ebna1-specific cytotoxic t-lymphocytes
genetically modified t cells # 1138
in111 anti-cd45 monoclonal antibody bc8
in111 monoclonal antibody lym-1
levorphanol tartrate (levo-dromoran)
lmp-specific cytotoxic t-lymphocytes
monoclonal antibody mono-dga-rfb4
multi-virus-specific cytotoxic t lymphocytes
Organization Involved with Phase 4 Indications (70)
Asociacion Espanola de Hematologia y Hemoterapia
Badalona Hospital Germans Trias i Pujol
Case Western Reserve University
Chinese Academy of Medical Sciences
Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon
Huazhong University of Science and Technology
Justus Liebig University Giessen
Polish Lymphoma Research Group
Shijiazhuang Pharma Group (CSPC)
Taipei Veteran General hospital
Organization Involved with Phase 3 Indications (296)
American Scitech International
Arbeitsgemeinschaft medikamentoese Tumortherapie
ASO SS Antonio e Biagio e C Arrigo Alessandria, Italy
Australasian Leukaemia and Lymphoma Group
Azienda Ospedaliera San Giovanni Battista
Beijing InnoCare Pharma Tech Co., Ltd.
Blood and Marrow Transplant Clinical Trials Network
British Columbia Cancer Agency
Cancer and Leukemia Group B (CALGB)
Center for International Blood and Marrow Transplant Research
Centre Hospitalier Schaffner France
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Children's Cancer and Leukaemia Group
Children's Cancer Group, China
Chinese Anti-Cancer Association
City of Hope National Medical Center
Cohen Children's Medical Center of New York
Eastern Cooperative Oncology Group
EBMT Solid Tumors Working Party
ECOG-ACRIN Cancer Research Group
European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma
European Mantle Cell Lymphoma Network
Fondazione Italiana Diabete Onlus
French Innovative Leukemia Organisation
French Study Group on Chronic Lymphoid Leukemia
German Federal Ministry of Education and Research
German High-Grade Non-Hodgkin's Lymphoma Study Group
German Hodgkin's Lymphoma Study Group
German Low Grade Lymphoma Study Group
Grup per l'Estudi dels Limfomes de Catalunya i Balears
Gruppo Italiano Malattie EMatologiche dell'Adulto
Gruppo Italiano Studio Linfomi
Gruppo Italiano Terapie Innovative nei Linfomi
Gruppo Italiano Trapianto di Midollo Osseo
Hematology Oncology Associates of the Palm Beaches
Herbert Irving Comprehensive Cancer Center
Hoosier Cancer Research Network
HOVON - Dutch Haemato-Oncology Association
Innovent Biologics (Suzhou) Co. Ltd.
International Extranodal Lymphoma Study Group
Jiangsu Cancer Institute & Hospital
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Katholieke Universiteit Leuven
Laboratorio Elea S.A.C.I.F. y A.
Maria Sklodowska Curie Children's Hospital
Medical University of South Carolina
Memorial Sloan-Kettering Cancer Center
Moorgreen Hospital, Southampton
Nanjing Yoko Biomedical Co., Ltd.
National Center for Research Resources (NCRR)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Oregon Health and Science University
Pirogov Russian National Research Medical University
Royal Liverpool & Broadgreen University Hospitals NHS Truts
Russian Academy of Medical Sciences
Scotland and Newcastle Lymphoma Group
Shandong Lanjin Pharmaceuticals Co.,Ltd
Shanghai CP Guojian Pharmaceutical Co.,Ltd.
Societe Francaise Oncologie Pediatrique
State University of New York, Buffalo
St. Joseph's Children's Hospital of Tampa
Swiss Group for Clinical Cancer Research
Taunton and Somerset NHS Foundation Trust
Technical University of Dresden
The Lymphoma Academic Research Organisation
The Lymphoma Study Association
Trans Tasman Radiation Oncology Group
United Kingdom Children's Cancer Study Group
Universidad Complutense de Madrid
Université catholique de Louvain
University of Alabama, Birmingham
University of California, Los Angeles
University of California, San Francisco
University of Erlangen-Nuremberg
University of Modena and Reggio Emilia
University of North Carolina at Chapel Hill
U.O.A. di Ematologia Azienda Ospedale S. Maria Nuova
U.O.A. di Ematologia Ospedale Molinette
Virginia Commonwealth University
Organization Involved with Phase 2 Indications (631)
Academic and Community Cancer Research United
Acetylon Pharmaceuticals Incorporated
All India Institute of Medical Sciences
American Society of Clinical Oncology
Apogee Biotechnology Corporation
Asociacion Doctor Peset Para el Estudio de la Hematología
Assistance Publique - Hôpitaux de Paris
Azienda Ospedaliera Antonio Cardarelli
Azienda Ospedaliera S. Croce e Carle Cuneo
Azienda Osperdaliera Vincenzo Cervello Divisione
Beijing Biohealthcare Biotechnology Co.,Ltd
Beijing Mabworks Biotech Co., Ltd.
Big Ten Cancer Research Consortium
Boca Raton Clinical Research Associates
Boryung Pharmaceutical Company
Bronx River Medical Associates, PC
Cancer Biotherapy Research Group
Cancer Care Centers of South Texas , San Antonio
Cancer Care Clinic and Hospital, Nagpur, India
Cancer Treatment Centers of America
Cantonal Hospital of St. Gallen
Central Maryland Oncology Center
Centro di Riferimento Oncologico - Aviano
Centro Medico Nacional La Raza, IMSS
Children's National Medical Center
China Food and Drug Administration
Chongqing Precision Biotech Co., Ltd
Ciusss de L'Est de l'Île de Montréal
Clinica Universidad de Navarra
Complessa di Ematologia and Dir Departmento
Consortium for Improving Survival of Lymphoma
Cyclacel Pharmaceuticals, Inc.
Damon Runyon Cancer Research Foundation
Danish Child Cancer Foundation
Department of Lymphoma and Hematology, Hunan Cancer Hospital
Deutsche AIDS Gesellschaft e.V.
Developmental Therapeutics Consortium
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Dr. Bernard Verbeeten Instituut
Drs Pirjol, Szpak and Moodley Inc, Durban, South Africa
Dynavax Technologies Corporation
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Federal University of Rio Grande do Sul
Franklin Square Hospital Center
French National Agency for Research on AIDS and Viral Hepatitis
Fundacao Hospital Amaral Carvalho
Fundación Leucemia y Linfoma, Spain
Gemeinschaftspraxis Porowski & Koniczek, Heilbronn, Germany
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Groupe Hospitalier Public Sud Oise
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
GRUPPO ITALIANO TERAPIE INNOVATIVE NEI LINFOMI
Guangzhou Gloria Biosciences Co., Ltd.
Hangzhou Zenshine Pharmaceuticals Co., Ltd.
Henan University of Traditional Chinese Medicine
Hoag Memorial Hospital Presbyterian
Hôpital Maisonneuve Rosemont, Montréal, QC, Canada
Hospital de Clinicias da UICAMP
Hospital Dr. Jose Molina Orosa
Hospital Fundación de Alcorcon
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Hospital Nossa Senhora da Conceicao
Hospital Santa Marcelina, Sao Paulo, Brasil
Hospital Universitario Arnau de Vilanova de Lleida
Hospital Universitario Central de Asturias
Hospital Universitario Puerta del Mar
Hospital Universitari Son Dureta
Huizhou People's Central Hospital
Icahn School of Medicine at Mount Sinai
ImmunoVaccine Technologies, Inc.
Innovative Cellular Therapeutics Co., Ltd.
Innovative Therapies For Children with Cancer Consortium
Institut Català d'Oncologia, Hospital Duran i Reynals
Institute for Oncology and Radiology Serbia
Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti
Instytut Hematologii i Transfuzjologii, 02-776 Warszawa ul. Indiry Gandhi 14
Isala Clinics, Zwolle, The Netherlands
Istituto Clinico Humanitas - Rozzano (MI), Italy
Istituto Nazionale per lo Studio e la Cura dei Tumori
Istitutp di Ematologia ed Oncologia Medica
James Graham Brown Cancer Center
Jaslok Hospital and Research Centre, Mumbai, India
Jiangxi Provincial Cancer Hospital
Johannes Wesling Klinikum, Minden, Germany
Josep Carreras Leukaemia Research Institute
Kecellitics Biotech Company Ltd
Koordinierungszentren für Klinische Studien bzw. Zentren für klinische Studien
La Jolla Pharmaceutical Company
Liberty Hematology and Oncology
Lymphoma Disease Committee of TCOG
Malabar Institute of Medical Sciences
Medical City Children's Hospital, Dallas
Meenakshi Ammal Dental College and Hospital
Methodist Cancer Center, Houston, Texas
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
National Cancer Institute, France
National Cheng Kung University
National Comprehensive Cancer Network
National Institute on Aging (NIA)
National Natural Science Foundation of China
National University of Singapore
Nordic Society for Pediatric Hematology and Oncology
North Central Cancer Treatment Group
Norwegian University of Science and Technology
Ospedale degli Infermi di Biella
Ospedale Maggiore Azienda Sanitaria Universitaria Trieste Ematologia
Ospedale Santa Croce-Carle Cuneo
Ospedale S. Giovanni Bellinzona
Our Lady of Mercy Medical Center
Pavlov First Saint Petersburg State Medical University
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Philipps University of Marburg
Prologue Research International
Quebec Clinical Research Organization in Cancer
Radiation Therapy Oncology Group
Rajiv Gandhi University of Health Sciences
Rochester Skin Lymphoma Medical Group, PLLC
Royal Marsden Hospital NHS Trust
Samyang Biopharmaceuticals Corporation
Service Clinique des Maladies du Sang
Shandong New Time Pharmaceutical Co., LTD
Shanghai Ming Ju Biotechnology Co., Ltd.
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Shanghai YingLi Pharmaceutical Co. Ltd.
Shenzhen Geno-Immune Medical Institute
Shenzhen Hank Bioengineering Institute
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Simcere Pharmaceutical Co., Ltd
Southampton University Hospital NHS Foundation Trust
South-Eastern Norway Regional Health Authority
Southern Europe New Drug Organization (SENDO)
Spanish National Health System
St. John Hospital and Medical Center, Van Elslander Cancer Center
Taichung Veterans General Hospital
TaiGen Biotechnology Co., Ltd.
Tayu Huaxia Biotech Medical Group Co., Ltd.
Technical University of Munich
Territorial Hospital Group (GHT) Rance Emeraude
The Alvin and Lois Lapidus Cancer Institute
The Beijing Pregene Science and Technology Company, Ltd.
The Foundation Institute San Raffaele G. Giglio of Cefalù
The Leukemia and Lymphoma Society
The Scientific and Technological Research Council of Turkey
The Wayne D. Kuni and Joan E. Kuni Foundation
Translational Research Institute for Metabolism and Diabetes, Florida
Universidad Autonoma de Barcelona
Universidad Autonoma de Madrid
Universidad Autonoma de Nuevo Leon
Universidade Federal do Parana
Universitario de Santiago, Spain
University Hospital Plymouth NHS Trust
University of California, Davis
University of California, Irvine
University of California, San Diego
University of Colorado, Denver
University of Illinois at Chicago
University of Las Palmas de Gran Canaria
University of Medicine and Dentistry of New Jersey
University of Nice Sophia Antipolis
University of Picardie Jules Verne
University of Roma La Sapienza
University of Southern California
University of Southern Denmark
University of Texas, San Antonio
University of the Republic of Srpska
University of Western Brittany
Vita-Salute University of Milano. Italy
Zhangzhou Municipal Hospital of Fujian Province
Organization Involved with Phase 1 Indications (210)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Aeon Therapeutics (Shanghai) Co., Ltd.
Allife Medical Science and Technology Co., Ltd.
Australian Department of Industry, Tourism and Resources
Beijing Doing Biomedical Co., Ltd.
Beijing GD Initiative Cell Therapy Technology Co.，Ltd.
Beijing Immunochina Medical Science & Technology Co., Ltd.
Bharath Hospital and Institute of Oncology
Bio-Cancer Treatment International Limited
British Society for Haematology
California Institute for Biomedical Research
California Institute for Regenerative Medicine (CIRM)
Cancer Centres of the Carolinas, Greenville, SC 29605
Cancer Immunotherapy Trials Network
Cellular Biomedicine Group Ltd.
Children's Hospital Los Angeles
CLL Global Research Foundation
Cook Children's Medical Center
Curon Biopharmaceutical (Australia) Co Pty Ltd
Department of Health and Human Services
Generon (Shanghai) Corporation Ltd.
Hangzhou HeZheng Pharmaceutical Co., Ltd
Hebei Senlang Biotechnology Inc., Ltd.
Henan Hualong Biotechnology Company
HonorHealth Research Institute
Illawarra Cancer Care Centre (Wollongong)
Infinity Pharmaceuticals, Inc.
Ludwig Institute for Cancer Research
Malaghan Institute of Medical Research
Marino Biotechnology Co., Ltd.
MingSight Pharmaceuticals Pty Limited
Nanjing Bioheng Biotech Co., Ltd.
National Health and Medical Research Council, Australia
New Mexico Cancer Care Alliance
Olivia Newton-John Cancer Research Institute
Oncology Institute of Southern Switzerland
Pediatric Brain Tumor Consortium
Shanghai Cell Therapy Engineering Research Institute
Shanghai Cell Therapy Group Co.,Ltd
Shanghai Celluar Biopharmaceutical Group Ltd.
Shanghai Jiatan Pharmatech Co., Ltd
Shanghai Junshi Bioscience Co.,Ltd.
Sinobioway Cell Therapy Co., Ltd.
South Plains Oncology Consortium
South Texas Accelerated Research Therapeutics
Sylvester Comprehensive Cancer Center
The Jewish General Hospital, Montreal QC, Canada
Translational Drug Development
Triphase Research and Development Corporation
Union Stem Cell & Gene Engineering Co.LTD
University of British Columbia
University of California, Berkeley
Wellington Zhaotai Therapies Limited
Wuhan Bio-Raid Biotechnology Co, Ltd. China
Organization Involved with Other Experimental Indications (15)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
